SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention after a sharp rally and elevated trading activity, with traders pointing to Starknets privacy features, Bitcoin DeFi plans, and post-quantum security as potential catalysts. The reaction is divided between optimism about the projects technology and concerns that the move could be a speculative pump amid token-unlock selling pressure.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a price rebound, with traders discussing entry points and renewed interest in Bittensors decentralized-AI theme. Some link the move to a broader AI-token rally and speculate that China could ease crypto restrictions, but that claim is unconfirmed; others remain cautious about volatility.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH is drawing attention after a mixed Q2 earnings report and updated outlook; traders are debating whether the strong adjusted earnings result reflects improving business momentum or was materially helped by tariff refunds, with concerns about underlying demand and debt. Bears expect further weakness, while some bulls see the selloff as a buying opportunity and point to potential short-squeeze interest.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is gaining alongside vaccine stocks after reports of an NIH-backed push to accelerate personalized cancer vaccines, though traders note the company and Genentech halted a colorectal cancer vaccine trial after weak efficacy results. The community is also comparing BNTXs move with Modernas stronger rally and debating how much BioNTechs oncology pipeline stands to benefit.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention for choppy consolidation after a rebound, with traders sharing technical setups and debating whether it can break resistance or retreat toward support. Bullish calls tied to broader crypto optimism contrast with concerns that BNB has been weak and the move may fade.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is drawing attention amid a volatile rebound in gold miners after a correction tied to weakness in gold and concerns about higher rates and Treasury yields. Traders are divided on whether the upswing signals a durable turn or a temporary bounce, with some watching for confirmation while others expect further downside.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Attention centers on reported Solana selection of SQD and the broader enterprise-adoption story around its blockchain data-indexing network, with traders also citing Google Cloud and Robinhood integrations. Many are bullish on expanding usage, while others question whether adoption will translate into token value and warn that the volatile move may be speculative; further Google news and a buyback remain speculation.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Cathie Woods portfolio moves and ARKKs track record are driving discussion, with traders criticizing her timing and past underperformance while others point to the funds recent rebound and bullish breakout setups. The debate reflects whether ARKKs concentrated, volatile growth strategy is recovering or remains vulnerable to sharp swings.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis Inc - Ordinary Shares - Class A

Zoetis is drawing attention after a steep decline amid slowing sales and reduced growth expectations, with traders debating whether the selloff has made the animal-health company a value opportunity or signals deeper demand and execution problems. Michael Burrys reported additions have fueled dip-buying and skepticism, while some traders also point to the FDAs conditional approval of Zoetiss screwworm treatment as a potential positive.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows steep selloff is being discussed in connection with its latest earnings and weaker residential outlook: traders note revenue growth but are concerned that softer housing activity and high mortgage rates are weighing on guidance. Some bulls view the decline as an overreaction to a still-growing business, while bears point to persistent housing-market and competitive pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will participate in the following upcoming investor...

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead...

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline...

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of...

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study...

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. We are thrilled...

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni...

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported...

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Alto Neuroscience (ANRO) Projected to Post Earnings on Wednesday

Alto Neuroscience (NYSE:ANRO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$24.37
Prev Close	$24.03
Open	$24.00
Dividend Yield	0.00%
50-Day Moving Average	$30.54
Beta	1.67
Avg. Volume	594,999.29
PE Ratio	-9.85

52-Week High	$37.48
52-Week Low	$5.23
Market Capitalization	$956.33M
EPS (Annual)	-$2.19
Price to Book	3.90
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANRO Fundamentals